Sai Parenteral's Ltd

Sai Parenterals Ltd share price declined 7.74% to Rs 480.65. The Company's net profit jumped 32.70% to Rs 10.51 crore, while revenue from operations improved marginally 9.09% to Rs 194.92 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.72 lakh crore, rising 4.75%. It has improved by 2.16% over last one week and gained upto 0.86% in last one month while the market capitalization of Sai Parenterals Ltd has inched up 0.43% and 7.29% in the same period respectively. Profit before tax (PBT) of Sai Parenterals Ltd stood at Rs 9.89 crore in Q3 FY26, gaining 8.09% year-on-year, and easing 1.02% quarter-on-quarter. EBITDA came in at Rs 37 crore, surging by 261.94% YoY and jumping 84.63% sequentially. Total expenses increased by 10.11% to Rs 179.77 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 82.24 crore, tumbling by 29.18% YoY, while employee benefits expense was at Rs 12.86 crore, rising by 11.44% YoY. For the TTM ended FY26, revenue from operations jumped by 133.58% to Rs 381.0 crore, while net profit slipped by 1.18% to Rs 14.26 crore, compared to previous TTM. EBITDA soared by 4639% to Rs 30.18 crore, and PBT plunged by 40.08% to Rs 11.93 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 93.05 crore in FY26, as against Rs 33.15 crore in FY25. Sai Parenterals Ltd rallied 18.27% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 9.87% during the same period.

Sai Parenterals Ltd share price inched up 2.80% to Rs 521.0 after the company's net profit surged by 32.70% to Rs 10.51 crore, while revenue from operations improved marginally 9.09% to Rs 194.92 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.66 lakh crore, rising 4.55%. It has marginally improved by 4.66% over last one week and moved up slightly by 1.10% in last one month while the market capitalization of Sai Parenterals Ltd has gained 14.47% and 1.93% in the same period respectively. Profit before tax (PBT) of Sai Parenterals Ltd stood at Rs 9.89 crore in Q3 FY26, easing 8.09% year-on-year, and gaining 1.02% quarter-on-quarter. EBITDA came in at Rs 37 crore, surging by 261.94% YoY and jumping 84.63% sequentially. Total expenses went up by 10.11% to Rs 179.77 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 82.24 crore, slumping by 29.18% YoY, while employee benefits expense was at Rs 12.86 crore, registering a growth of 11.44% YoY. For the TTM ended FY26, revenue from operations witnessed a strong growth of 133.58% to Rs 381.0 crore, while net profit eased 1.18% to Rs 14.26 crore, compared to previous TTM. EBITDA jumped by 4639% to Rs 30.18 crore, and PBT tanked by 40.08% to Rs 11.93 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 93.05 crore in FY26, as against Rs 33.15 crore in FY25. Sai Parenterals Ltd rallied 28.20% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 11.78% during the same period.

Sai Parenterals Limited will hold a board meeting on Sunday, 01st November, 2026, to consider the un-audited financial results (standalone and consolidated) for the quarter and half year ended 30th September, 2026, and a limited review report for the same period. The company’s trading window will remain closed for designated persons and their immediate relatives until 48 hours after the declaration of the financial results.

Sai Parenterals Limited will close its trading window for designated persons, their immediate relatives, and connected persons from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ended September 30, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Sai Parenterals Limited announced that its subsidiary, Noumed Pharmaceuticals Pty Limited, has renewed a long-term Over-the-Counter (OTC) Medicines Supply Agreement with a leading Australian pharmacy chain, featuring an expanded product portfolio and a three-year term. The renewed agreement is valued at AUD 30 million, which equates to approximately Rs 204 Crores based on an exchange rate of Rs 68.52 per AUD, and does not involve any related party transactions or interest from the company's promoters or group entities. The effective date of the agreement is August 24, 2026.

Sai Parenterals Ltd share price declined by 1.35% to Rs 579.4 after the company's net profit plunged by 39.82% to Rs 7.92 crore, while revenue from operations slipped slightly by 9.73% to Rs 178.67 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.12 lakh crore, gaining 4.41%. It has improved by 1.16% over last one week and advanced by 11.70% in last one month while the market capitalization of Sai Parenterals Ltd has gained 11.76% and 20.76% in the same period respectively. Profit before tax (PBT) of Sai Parenterals Ltd stood at Rs 9.79 crore in Q2 FY26, jumping 387.06% year-on-year, and crashing by 20.98% quarter-on-quarter. EBITDA came in at Rs 20 crore, surging by 452.51% YoY and dropping 14.78% sequentially. Total expenses softened by 9.31% to Rs 163.26 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 116.12 crore, growing marginally by 1.73% YoY, while employee benefits expense was at Rs 11.54 crore, registering a marginal contraction of 5.56% YoY. For the TTM ended FY26, revenue from operations posted a slight growth of 6.08% to Rs 163.11 crore, while net profit saw a strong growth of 71.38% to Rs 14.43 crore, compared to previous TTM. EBITDA jumped by 2802% to Rs 38.74 crore, and PBT soared 58.52% to Rs 19.91 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 33.15 crore in FY26, as against Rs 29.76 crore in FY25.

Sai Parenterals Limited informed the Bombay Stock Exchange and National Stock Exchange that there were no deviations or variations in the utilization of proceeds from its Initial Public Offer (IPO) during the quarter ended June 30, 2026, as per Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company had raised Rs 2,850 million through the IPO from March 24, 2026, to March 27, 2026.

Sai Parenterals Limited will hold a board meeting on Tuesday, August 11, 2026, at its registered office to consider unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2026, and a limited review report (standalone and consolidated) for the same period, according to a filing with the BSE Limited and NSE Limited.

Sai Parenterals announced that the company's subsidiary Noumed Pharmaceuticals had entered OTC medicines supply agreement with Australia's leading pharmacy network with contract valued at Australian Dollars (AUD) 202 millions (equivalent to Rs 1300 crore; 1 AUD = INR 64.5). The agreement is valid for a period of 7.5 years with a further option of 3 years extension upon mutual consent.

Sai Parenterals has received a purchase order valued at USD 11 million at an exchange rate of Rs 95 (Rs 104.50 crore) from PILL CORP, Bulacan, Philippines. The contract is for supply of anti TB products for the Philippines market on exclusivity basis for a period of 10 years.